Blinatumomab...Past, Present, and Future-blinatumomab...past,_present,_and_future

Video Transcription

Video Summary

The presentation reviewed Blenatumomab’s mechanism, nursing considerations, and evolving role in pediatric B-cell ALL. Blinatumomab is a bispecific T-cell engager that links CD3 on T cells to CD19 on B cells, helping destroy CD19-positive leukemia cells. Key administration points include continuous IV infusion over 28 days via a dedicated central line, avoiding flushing, using dexamethasone premedication, and carefully managing interruptions longer than four hours. The speaker emphasized inpatient and outpatient safety planning, staff and family education, neuro checks, backup bags, and pump troubleshooting. Common toxicities include cytokine release syndrome, neurotoxicity, infection, and transaminitis. The talk also covered expanded use in frontline therapy, especially after COG trial results showed improved disease-free survival when added to chemotherapy. Future questions include optimal supportive care, infection prevention, cycle timing, long-term outcomes, and possible subcutaneous formulations.

Keywords

Blinatumomab

pediatric B-cell ALL

bispecific T-cell engager

continuous IV infusion

cytokine release syndrome

neurotoxicity